Unlock instant, AI-driven research and patent intelligence for your innovation.

United use of LGR4/RSPO blocker and anti-immune check point inhibitor to immunotherapy of tumors

A technology of immune checkpoints and blockers, applied in the direction of anti-tumor drugs, antibody medical components, antibodies, etc., can solve the problems of limiting tumor broad-spectrum action and low response

Active Publication Date: 2019-10-18
BIORAY LABORATORIES INC
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Some patients have no response or low response to this type of drug, which severely limits the broad-spectrum effect of this type of drug on specific types of tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • United use of LGR4/RSPO blocker and anti-immune check point inhibitor to immunotherapy of tumors
  • United use of LGR4/RSPO blocker and anti-immune check point inhibitor to immunotherapy of tumors
  • United use of LGR4/RSPO blocker and anti-immune check point inhibitor to immunotherapy of tumors

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0142] Antibody preparation

[0143] Any method suitable for producing monoclonal antibodies can be used to produce anti-immune checkpoints (such as PD-1, PD-L1, CTLA-4, TIM3, TIGIT\ICOS, LAG3, OX40, CD47, VISTA, 4- 1BB) antibodies. For example, linked or naturally occurring immune checkpoints (such as PD-1, PD-L1, CTLA-4, TIM3, TIGIT\ICOS, LAG3, OX40, CD47, VISTA, 4-1BB) homodimers or Fragments thereof are used to immunize animals. Suitable immunization methods may be used, including adjuvants, immunostimulants, repeated booster immunizations, one or more routes may be used.

[0144] Any suitable form of immune checkpoint (such as PD-1, PD-L1, CTLA-4, TIM3, TIGIT\ICOS, LAG3, OX40, CD47, VISTA, 4-1BB) can be used as an immunogen (antigen) for Generate non-human antibodies specific to immune checkpoints (such as PD-1, PD-L1, CTLA-4, TIM3, TIGIT\ICOS, LAG3, OX40, CD47, VISTA, 4-1BB), and screen the biology of the antibodies active. The eliciting immunogen can be a full-leng...

Embodiment 1

[0227] Example 1 Construction of Lgr4 prokaryotic expression vector and expression and purification of Lgr4 extracellular segment protein

[0228] The Lgr4 prokaryotic expression vector was constructed by the applicant in the early stage. The expression vector skeleton used was PET28a(+). The polynucleotide sequence of the LGR4 gene was connected into its multiple cloning site through genetic engineering operation technology. After expression, the extracellular segment of the target protein Lgr4 Protein N-terminal fusion expresses 6×his-tagged protein. Transform BL21 Escherichia coli with the recombinant plasmid, and coat the LB agarose culture plate with kanamycin resistance. After culturing overnight, pick a single positive colony and place it in the LB liquid medium containing kanamycin resistance for shaking culture. Overnight, transfer all the overnight bacterial liquid into 1L of fresh LB liquid medium containing kanamycin resistance, shake the bacteria at 37°C and 220rp...

Embodiment 2

[0246] Example 2 Anti-tumor effect of LGR4 / Rspondin blocker synergistically with PD-1 antibody

[0247] LGR4-ECD can block the interaction between LGR4 and Rspondin1, Rspondin2, Rspondin3, Rspondin4, and Rspondin1 antibody can block the interaction between LGR4 and Rspondin1.

[0248] The present invention uses C57BL / 6 mice to establish a subcutaneous melanoma model of B16F10, and the tumor-forming mice with uniform tumor volume are given LGR4-ECD, anti-Rspondin1 monoclonal antibody, and anti-PD-1 monoclonal antibody respectively. Single drug and combined drug treatment to detect and evaluate the synergistic effect of blockade of Rspondin / lgr4 signaling on the therapeutic effect of anti-PD-1 monoclonal antibody.

[0249] The result is as figure 2 shown. The results show that the LGR4 / Rspondin blocker LGR4-ECD can significantly enhance the anti-tumor effect of the immune checkpoint PD-1 antibody and prolong the survival of tumor-bearing mice; the LGR4 / Rspondin blocker RSPO1 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to united use of an LGR4 / RSPO blocker and an anti-immune check point inhibitor to immunotherapy of tumors, in particular to a product combination. The product combination comprises (i) a first medical composition, wherein the first medical composition comprises (a) first active components which are an LGR4 / RSPO blocker and a pharmaceutically acceptable carrier; and (ii) a second medical composition, wherein the second medical composition comprises (b) second active components which are the anti-immune check point inhibitor, anti-immune check points are selected from PD-1,PD-L1, CTLA-4, TIM3, TIGIT\ICOS, LAG3, OX40, CD47, VISTA, 4-1BB or combination thereof, and the pharmaceutically acceptable carrier. The united use of an LGR4 / RSPO blocker and an anti-immune check point inhibitor to immunotherapy of tumors can be effectively used for (i) treating tumors; (ii) restraining tumor growth; (iii) restraining antineoplastic activity of tumor-associated macrophages cellsin tumor microenvironment; and / or (iv) improving sensibility of tumors to an anti-immune check point treatment method.

Description

technical field [0001] The invention relates to the field of immunotherapy, in particular to the combination of LGR4 / RSPO blocker and anti-immune checkpoint inhibitor for tumor immunotherapy. Background technique [0002] Malignant tumor, also known as cancer, is a serious disease that seriously endangers human health. According to the statistics of the World Health Organization, there are more than 8 million cases of malignant tumors in the world every year, and the incidence rate is still on the rise. [0003] In the course of fighting against malignant tumors, people have developed and developed a variety of means to deal with malignant tumors, from the initial surgical resection to further development to drug chemotherapy, radiation therapy, targeted therapy, etc., which greatly enriched the treatment of malignant tumors. The treatment methods have also achieved remarkable clinical therapeutic effects, which obviously alleviated the symptoms of patients, improved their ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K39/395A61P35/00
CPCA61K45/06A61K39/395A61P35/00A61K39/00A61K38/17
Inventor 谭炳合杜冰刘明耀张亮席在喜
Owner BIORAY LABORATORIES INC